Proteomic Profiling Differentiates Lymphoma Patients with and without Concurrent Myeloproliferative Neoplasia

Myeloproliferative neoplasia (MPN) and lymphoma are regarded as distinct diseases with different pathogeneses. However, patients that are diagnosed with both malignancies occur more frequently in the population than expected. This has led to the hypothesis that the two malignancies may, in some case...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Johanne Marie Holst, Marie Beck Enemark, Martin Bjerregaard Pedersen, Kristina Lystlund Lauridsen, Trine Engelbrecht Hybel, Michael Roost Clausen, Henrik Frederiksen, Michael Boe Møller, Peter Nørgaard, Trine Lindhardt Plesner, Stephen Jacques Hamilton-Dutoit, Francesco d’Amore, Bent Honoré, Maja Ludvigsen
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	angioimmunoblastic T-cell lymphoma (AITL) diffuse large B-cell lymphoma (DLBCL) myeloproliferative neoplasia (MPN) proteomics Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/09160659454e4d86851008de2cdea10b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:09160659454e4d86851008de2cdea10b
record_format	dspace
spelling	oai:doaj.org-article:09160659454e4d86851008de2cdea10b2021-11-11T15:33:53ZProteomic Profiling Differentiates Lymphoma Patients with and without Concurrent Myeloproliferative Neoplasia10.3390/cancers132155262072-6694https://doaj.org/article/09160659454e4d86851008de2cdea10b2021-11-01T00:00:00Zhttps://www.mdpi.com/2072-6694/13/21/5526https://doaj.org/toc/2072-6694Myeloproliferative neoplasia (MPN) and lymphoma are regarded as distinct diseases with different pathogeneses. However, patients that are diagnosed with both malignancies occur more frequently in the population than expected. This has led to the hypothesis that the two malignancies may, in some cases, be pathogenetically related. Using a mass spectrometry-based proteomic approach, we show that pre-treatment lymphoma samples from patients with both MPN and lymphoma, either angioimmunoblastic T-cell lymphoma (MPN-AITL) or diffuse large B-cell lymphoma (MPN-DLBCL), show differences in protein expression compared with reference AITL or DLBCL samples from patients without MPN. A distinct clustering of samples from patients with and without MPN was evident for both AITL and DLBCL. Regarding MPN-AITL, a pathway analysis revealed disturbances of cellular respiration as well as oxidative metabolism, and an immunohistochemical evaluation further demonstrated the differential expression of citrate synthase and <i>DNAJA2</i> protein (<i>p</i> = 0.007 and <i>p</i> = 0.015). Interestingly, <i>IDH2</i> protein also showed differential expression in the MPN-AITL patients, which contributes to the growing evidence of this protein’s role in both myeloid neoplasia and AITL. In MPN-DLBCL, the disturbed pathways included a significant downregulation of protein synthesis as well as a perturbation of signal transduction. These results imply an underlying disturbance of tumor molecular biology, and in turn an alternative pathogenesis for tumors in these patients with both myeloid and lymphoid malignancies.Johanne Marie HolstMarie Beck EnemarkMartin Bjerregaard PedersenKristina Lystlund LauridsenTrine Engelbrecht HybelMichael Roost ClausenHenrik FrederiksenMichael Boe MøllerPeter NørgaardTrine Lindhardt PlesnerStephen Jacques Hamilton-DutoitFrancesco d’AmoreBent HonoréMaja LudvigsenMDPI AGarticleangioimmunoblastic T-cell lymphoma (AITL)diffuse large B-cell lymphoma (DLBCL)myeloproliferative neoplasia (MPN)proteomicsNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCancers, Vol 13, Iss 5526, p 5526 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	angioimmunoblastic T-cell lymphoma (AITL) diffuse large B-cell lymphoma (DLBCL) myeloproliferative neoplasia (MPN) proteomics Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	angioimmunoblastic T-cell lymphoma (AITL) diffuse large B-cell lymphoma (DLBCL) myeloproliferative neoplasia (MPN) proteomics Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Johanne Marie Holst Marie Beck Enemark Martin Bjerregaard Pedersen Kristina Lystlund Lauridsen Trine Engelbrecht Hybel Michael Roost Clausen Henrik Frederiksen Michael Boe Møller Peter Nørgaard Trine Lindhardt Plesner Stephen Jacques Hamilton-Dutoit Francesco d’Amore Bent Honoré Maja Ludvigsen Proteomic Profiling Differentiates Lymphoma Patients with and without Concurrent Myeloproliferative Neoplasia
description	Myeloproliferative neoplasia (MPN) and lymphoma are regarded as distinct diseases with different pathogeneses. However, patients that are diagnosed with both malignancies occur more frequently in the population than expected. This has led to the hypothesis that the two malignancies may, in some cases, be pathogenetically related. Using a mass spectrometry-based proteomic approach, we show that pre-treatment lymphoma samples from patients with both MPN and lymphoma, either angioimmunoblastic T-cell lymphoma (MPN-AITL) or diffuse large B-cell lymphoma (MPN-DLBCL), show differences in protein expression compared with reference AITL or DLBCL samples from patients without MPN. A distinct clustering of samples from patients with and without MPN was evident for both AITL and DLBCL. Regarding MPN-AITL, a pathway analysis revealed disturbances of cellular respiration as well as oxidative metabolism, and an immunohistochemical evaluation further demonstrated the differential expression of citrate synthase and <i>DNAJA2</i> protein (<i>p</i> = 0.007 and <i>p</i> = 0.015). Interestingly, <i>IDH2</i> protein also showed differential expression in the MPN-AITL patients, which contributes to the growing evidence of this protein’s role in both myeloid neoplasia and AITL. In MPN-DLBCL, the disturbed pathways included a significant downregulation of protein synthesis as well as a perturbation of signal transduction. These results imply an underlying disturbance of tumor molecular biology, and in turn an alternative pathogenesis for tumors in these patients with both myeloid and lymphoid malignancies.
format	article
author	Johanne Marie Holst Marie Beck Enemark Martin Bjerregaard Pedersen Kristina Lystlund Lauridsen Trine Engelbrecht Hybel Michael Roost Clausen Henrik Frederiksen Michael Boe Møller Peter Nørgaard Trine Lindhardt Plesner Stephen Jacques Hamilton-Dutoit Francesco d’Amore Bent Honoré Maja Ludvigsen
author_facet	Johanne Marie Holst Marie Beck Enemark Martin Bjerregaard Pedersen Kristina Lystlund Lauridsen Trine Engelbrecht Hybel Michael Roost Clausen Henrik Frederiksen Michael Boe Møller Peter Nørgaard Trine Lindhardt Plesner Stephen Jacques Hamilton-Dutoit Francesco d’Amore Bent Honoré Maja Ludvigsen
author_sort	Johanne Marie Holst
title	Proteomic Profiling Differentiates Lymphoma Patients with and without Concurrent Myeloproliferative Neoplasia
title_short	Proteomic Profiling Differentiates Lymphoma Patients with and without Concurrent Myeloproliferative Neoplasia
title_full	Proteomic Profiling Differentiates Lymphoma Patients with and without Concurrent Myeloproliferative Neoplasia
title_fullStr	Proteomic Profiling Differentiates Lymphoma Patients with and without Concurrent Myeloproliferative Neoplasia
title_full_unstemmed	Proteomic Profiling Differentiates Lymphoma Patients with and without Concurrent Myeloproliferative Neoplasia
title_sort	proteomic profiling differentiates lymphoma patients with and without concurrent myeloproliferative neoplasia
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/09160659454e4d86851008de2cdea10b
work_keys_str_mv	AT johannemarieholst proteomicprofilingdifferentiateslymphomapatientswithandwithoutconcurrentmyeloproliferativeneoplasia AT mariebeckenemark proteomicprofilingdifferentiateslymphomapatientswithandwithoutconcurrentmyeloproliferativeneoplasia AT martinbjerregaardpedersen proteomicprofilingdifferentiateslymphomapatientswithandwithoutconcurrentmyeloproliferativeneoplasia AT kristinalystlundlauridsen proteomicprofilingdifferentiateslymphomapatientswithandwithoutconcurrentmyeloproliferativeneoplasia AT trineengelbrechthybel proteomicprofilingdifferentiateslymphomapatientswithandwithoutconcurrentmyeloproliferativeneoplasia AT michaelroostclausen proteomicprofilingdifferentiateslymphomapatientswithandwithoutconcurrentmyeloproliferativeneoplasia AT henrikfrederiksen proteomicprofilingdifferentiateslymphomapatientswithandwithoutconcurrentmyeloproliferativeneoplasia AT michaelboemøller proteomicprofilingdifferentiateslymphomapatientswithandwithoutconcurrentmyeloproliferativeneoplasia AT peternørgaard proteomicprofilingdifferentiateslymphomapatientswithandwithoutconcurrentmyeloproliferativeneoplasia AT trinelindhardtplesner proteomicprofilingdifferentiateslymphomapatientswithandwithoutconcurrentmyeloproliferativeneoplasia AT stephenjacqueshamiltondutoit proteomicprofilingdifferentiateslymphomapatientswithandwithoutconcurrentmyeloproliferativeneoplasia AT francescodamore proteomicprofilingdifferentiateslymphomapatientswithandwithoutconcurrentmyeloproliferativeneoplasia AT benthonore proteomicprofilingdifferentiateslymphomapatientswithandwithoutconcurrentmyeloproliferativeneoplasia AT majaludvigsen proteomicprofilingdifferentiateslymphomapatientswithandwithoutconcurrentmyeloproliferativeneoplasia
_version_	1718435159678648320

Proteomic Profiling Differentiates Lymphoma Patients with and without Concurrent Myeloproliferative Neoplasia

Ejemplares similares